Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population

Patrick Hlavacek, Jennifer D. Guo, Lisa Rosenblatt, Allison Keshishian, Cristina Russ, Jack Mardekian, Mauricio Ferri, Tayla Poretta, Huseyin Yuce, Robert D McBane

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To compare safety, effectiveness, and healthcare costs of major bleeding (MB), clinically relevant non-major (CRNM) bleeding, recurrent venous thromboembolism (VTE), and all-cause hospitalization among elderly Medicare VTE patients prescribed warfarin vs apixaban. Methods: Using 100% Medicare data, elderly patients prescribed apixaban or warfarin within 30 days after a VTE encounter were identified. Patients had continuous health plan enrollment and no parenteral or oral anticoagulant use ≤6 months preceding the VTE encounter. Cohorts were balanced using 1:1 propensity score matching (PSM). Cox proportional hazard models were used to assess the risk of MB, CRNM bleeding, recurrent VTE, and all-cause hospitalization. Generalized linear and two-part models were used to estimate MB-, recurrent VTE-, and all-cause related costs (per patient per month [PPPM]). Results: In the pre-matched cohort, 25,284 (66.9%) patients were prescribed warfarin and 12,515 (33.1%) apixaban. After 1:1 PSM, 11,363 matched pairs of apixaban-warfarin patients were included for a mean follow-up of 4.0 and 4.4 months, respectively. Matched cohorts had a mean age of 78 years and mean Charlson Comorbidity Index score of 2.9. Warfarin was associated with a higher risk of MB (hazard ratio [HR] = 1.31; 95% confidence interval [CI] = 1.10–1.57) and CRNM bleeding (HR = 1.31; 95% CI = 1.19–1.43) vs apixaban. The risks of recurrent VTE (HR = 0.96; 95% CI = 0.70–1.33) and all-cause hospitalization (HR = 1.05; 95% CI = 0.99–1.12) were similar among warfarin and apixaban patients. Warfarin patients had higher MB-related ($147 vs $75; p =.003) and all-cause costs PPPM ($3,267 vs $3,033; p <.001), but similar recurrent VTE-related medical costs PPPM ($30 vs $36; p =.516) vs apixaban patients. Conclusions: Warfarin was associated with significantly higher risk of MB and CRNM bleeding as well as higher MB-related and all-cause costs vs apixaban patients. Recurrent VTE risk and costs were similar among warfarin and apixaban patients.

Original languageEnglish (US)
JournalCurrent Medical Research and Opinion
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Venous Thromboembolism
Warfarin
Medicare
Health Care Costs
Safety
Costs and Cost Analysis
Hemorrhage
Population
Confidence Intervals
Propensity Score
Hospitalization
apixaban
Proportional Hazards Models
Anticoagulants
Comorbidity

Keywords

  • apixaban
  • major bleeding
  • recurrent VTE
  • VTE
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. / Hlavacek, Patrick; Guo, Jennifer D.; Rosenblatt, Lisa; Keshishian, Allison; Russ, Cristina; Mardekian, Jack; Ferri, Mauricio; Poretta, Tayla; Yuce, Huseyin; McBane, Robert D.

In: Current Medical Research and Opinion, 01.01.2019.

Research output: Contribution to journalArticle

Hlavacek, Patrick ; Guo, Jennifer D. ; Rosenblatt, Lisa ; Keshishian, Allison ; Russ, Cristina ; Mardekian, Jack ; Ferri, Mauricio ; Poretta, Tayla ; Yuce, Huseyin ; McBane, Robert D. / Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. In: Current Medical Research and Opinion. 2019.
@article{5ae168bbcd354de5b9e31d8b57909f1d,
title = "Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population",
abstract = "Objective: To compare safety, effectiveness, and healthcare costs of major bleeding (MB), clinically relevant non-major (CRNM) bleeding, recurrent venous thromboembolism (VTE), and all-cause hospitalization among elderly Medicare VTE patients prescribed warfarin vs apixaban. Methods: Using 100{\%} Medicare data, elderly patients prescribed apixaban or warfarin within 30 days after a VTE encounter were identified. Patients had continuous health plan enrollment and no parenteral or oral anticoagulant use ≤6 months preceding the VTE encounter. Cohorts were balanced using 1:1 propensity score matching (PSM). Cox proportional hazard models were used to assess the risk of MB, CRNM bleeding, recurrent VTE, and all-cause hospitalization. Generalized linear and two-part models were used to estimate MB-, recurrent VTE-, and all-cause related costs (per patient per month [PPPM]). Results: In the pre-matched cohort, 25,284 (66.9{\%}) patients were prescribed warfarin and 12,515 (33.1{\%}) apixaban. After 1:1 PSM, 11,363 matched pairs of apixaban-warfarin patients were included for a mean follow-up of 4.0 and 4.4 months, respectively. Matched cohorts had a mean age of 78 years and mean Charlson Comorbidity Index score of 2.9. Warfarin was associated with a higher risk of MB (hazard ratio [HR] = 1.31; 95{\%} confidence interval [CI] = 1.10–1.57) and CRNM bleeding (HR = 1.31; 95{\%} CI = 1.19–1.43) vs apixaban. The risks of recurrent VTE (HR = 0.96; 95{\%} CI = 0.70–1.33) and all-cause hospitalization (HR = 1.05; 95{\%} CI = 0.99–1.12) were similar among warfarin and apixaban patients. Warfarin patients had higher MB-related ($147 vs $75; p =.003) and all-cause costs PPPM ($3,267 vs $3,033; p <.001), but similar recurrent VTE-related medical costs PPPM ($30 vs $36; p =.516) vs apixaban patients. Conclusions: Warfarin was associated with significantly higher risk of MB and CRNM bleeding as well as higher MB-related and all-cause costs vs apixaban patients. Recurrent VTE risk and costs were similar among warfarin and apixaban patients.",
keywords = "apixaban, major bleeding, recurrent VTE, VTE, Warfarin",
author = "Patrick Hlavacek and Guo, {Jennifer D.} and Lisa Rosenblatt and Allison Keshishian and Cristina Russ and Jack Mardekian and Mauricio Ferri and Tayla Poretta and Huseyin Yuce and McBane, {Robert D}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/03007995.2019.1653067",
language = "English (US)",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population

AU - Hlavacek, Patrick

AU - Guo, Jennifer D.

AU - Rosenblatt, Lisa

AU - Keshishian, Allison

AU - Russ, Cristina

AU - Mardekian, Jack

AU - Ferri, Mauricio

AU - Poretta, Tayla

AU - Yuce, Huseyin

AU - McBane, Robert D

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To compare safety, effectiveness, and healthcare costs of major bleeding (MB), clinically relevant non-major (CRNM) bleeding, recurrent venous thromboembolism (VTE), and all-cause hospitalization among elderly Medicare VTE patients prescribed warfarin vs apixaban. Methods: Using 100% Medicare data, elderly patients prescribed apixaban or warfarin within 30 days after a VTE encounter were identified. Patients had continuous health plan enrollment and no parenteral or oral anticoagulant use ≤6 months preceding the VTE encounter. Cohorts were balanced using 1:1 propensity score matching (PSM). Cox proportional hazard models were used to assess the risk of MB, CRNM bleeding, recurrent VTE, and all-cause hospitalization. Generalized linear and two-part models were used to estimate MB-, recurrent VTE-, and all-cause related costs (per patient per month [PPPM]). Results: In the pre-matched cohort, 25,284 (66.9%) patients were prescribed warfarin and 12,515 (33.1%) apixaban. After 1:1 PSM, 11,363 matched pairs of apixaban-warfarin patients were included for a mean follow-up of 4.0 and 4.4 months, respectively. Matched cohorts had a mean age of 78 years and mean Charlson Comorbidity Index score of 2.9. Warfarin was associated with a higher risk of MB (hazard ratio [HR] = 1.31; 95% confidence interval [CI] = 1.10–1.57) and CRNM bleeding (HR = 1.31; 95% CI = 1.19–1.43) vs apixaban. The risks of recurrent VTE (HR = 0.96; 95% CI = 0.70–1.33) and all-cause hospitalization (HR = 1.05; 95% CI = 0.99–1.12) were similar among warfarin and apixaban patients. Warfarin patients had higher MB-related ($147 vs $75; p =.003) and all-cause costs PPPM ($3,267 vs $3,033; p <.001), but similar recurrent VTE-related medical costs PPPM ($30 vs $36; p =.516) vs apixaban patients. Conclusions: Warfarin was associated with significantly higher risk of MB and CRNM bleeding as well as higher MB-related and all-cause costs vs apixaban patients. Recurrent VTE risk and costs were similar among warfarin and apixaban patients.

AB - Objective: To compare safety, effectiveness, and healthcare costs of major bleeding (MB), clinically relevant non-major (CRNM) bleeding, recurrent venous thromboembolism (VTE), and all-cause hospitalization among elderly Medicare VTE patients prescribed warfarin vs apixaban. Methods: Using 100% Medicare data, elderly patients prescribed apixaban or warfarin within 30 days after a VTE encounter were identified. Patients had continuous health plan enrollment and no parenteral or oral anticoagulant use ≤6 months preceding the VTE encounter. Cohorts were balanced using 1:1 propensity score matching (PSM). Cox proportional hazard models were used to assess the risk of MB, CRNM bleeding, recurrent VTE, and all-cause hospitalization. Generalized linear and two-part models were used to estimate MB-, recurrent VTE-, and all-cause related costs (per patient per month [PPPM]). Results: In the pre-matched cohort, 25,284 (66.9%) patients were prescribed warfarin and 12,515 (33.1%) apixaban. After 1:1 PSM, 11,363 matched pairs of apixaban-warfarin patients were included for a mean follow-up of 4.0 and 4.4 months, respectively. Matched cohorts had a mean age of 78 years and mean Charlson Comorbidity Index score of 2.9. Warfarin was associated with a higher risk of MB (hazard ratio [HR] = 1.31; 95% confidence interval [CI] = 1.10–1.57) and CRNM bleeding (HR = 1.31; 95% CI = 1.19–1.43) vs apixaban. The risks of recurrent VTE (HR = 0.96; 95% CI = 0.70–1.33) and all-cause hospitalization (HR = 1.05; 95% CI = 0.99–1.12) were similar among warfarin and apixaban patients. Warfarin patients had higher MB-related ($147 vs $75; p =.003) and all-cause costs PPPM ($3,267 vs $3,033; p <.001), but similar recurrent VTE-related medical costs PPPM ($30 vs $36; p =.516) vs apixaban patients. Conclusions: Warfarin was associated with significantly higher risk of MB and CRNM bleeding as well as higher MB-related and all-cause costs vs apixaban patients. Recurrent VTE risk and costs were similar among warfarin and apixaban patients.

KW - apixaban

KW - major bleeding

KW - recurrent VTE

KW - VTE

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85071872318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071872318&partnerID=8YFLogxK

U2 - 10.1080/03007995.2019.1653067

DO - 10.1080/03007995.2019.1653067

M3 - Article

C2 - 31387467

AN - SCOPUS:85071872318

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

ER -